Form 4: Mineralys CMO Sells Shares Under 10b5-1 Plan

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, executed a planned sale of common stock following an option exercise.

Summary

• Chief Medical Officer David Malcom Rodman of Mineralys Therapeutics, Inc. (MLYS) reported transactions involving company common stock.
• On May 18, 2026, Rodman acquired 417 shares of common stock at $15.44 per share through the exercise of a stock option.
• Concurrently, on May 18, 2026, Rodman sold 417 shares of common stock at $27.55 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
• Following these transactions, Rodman directly beneficially owns 63,443 shares of common stock and 4,167 stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned under a 10b5-1 plan, offsetting any potential negative signal from insider selling.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not reactive sale.
• The exercise of stock options demonstrates continued participation in the company's equity incentive program.

Negatives

• The sale of shares by a Chief Medical Officer, even if planned, reduces direct insider ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common and provide transparency into executive compensation and liquidity management, rather than necessarily signaling a change in company fundamentals or strategic direction.

Related Party Transactions

• The reported transactions involve the Chief Medical Officer of Mineralys Therapeutics, Inc. exercising stock options and selling common stock, which are considered related party transactions under SEC rules.

Stakeholder Impact

• Shareholders may observe a slight reduction in direct insider ownership, though the pre-planned nature of the sale mitigates concerns.
• Employees holding similar stock options may see this as a standard liquidity event for executives.

Key Dates

Recommendation

The transactions represent a routine, pre-planned insider sale following an option exercise, rather than a signal of fundamental change. As such, it does not warrant a change in investment posture based solely on this filing.

Keywords

Mineralys Therapeutics, MLYS, Insider Trading, Form 4, Stock Option Exercise, Share Sale, David Malcom Rodman, Chief Medical Officer, 10b5-1 Plan